BAM
TCRT icon

Belpointe Asset Management’s Alaunos Therapeutics TCRT Stock Holding History

Belpointe Asset Management’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-547
Closed -$262K – 625
2018
Q3 		$262K Buy
+547
New +$235K 0.04% 389
2018
Q1 		– Sell
-547
Closed -$339K – 468
2017
Q4 		$339K Sell
547
-263
-32% -$189K 0.07% 308
2017
Q3 		$746K Buy
+810
New +$719K 0.17% 126

Other funds holding TCRT

MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Belpointe Asset Management's TCRT Position: Q4 2018 in Review

Belpointe Asset Management sold out of Alaunos Therapeutics (TCRT) in Q4 2018, closing a stake of 547 shares — an estimated $262K sold.

Belpointe Asset Management first reported a position in TCRT in Q3 2017 and held it in 3 quarters. The position peaked at $746K in Q3 2017. 137 funds tracked by Wall St. Rank hold TCRT as of Q4 2018.

  • Belpointe Asset Management reported no remaining Alaunos Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Belpointe Asset Management sold 547 Alaunos Therapeutics shares in Q4 2018, an estimated $262K.
  • Belpointe Asset Management first reported a position in Alaunos Therapeutics in Q3 2017 and held it in 3 quarters.
  • Belpointe Asset Management's Alaunos Therapeutics position peaked at $746K in Q3 2017.
  • 137 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q4 2018.

Based on Belpointe Asset Management's 13F filing for Q4 2018, filed 6 Mar 2019.